NASDAQ · ABSI
Absci Corporation
$12.10+$0.22 (+1.85%)
Absci Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.55% below the high.
Loading market information…
NASDAQ · DRIO · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
DarioHealth Corp.’s quoted price sits in the lower half of its reported 52-week range, 77.59% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
DarioHealth Corp.’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$0.51. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow DarioHealth Corp.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
DarioHealth Corp. is a digital therapeutics enterprise operating across the United States, Canada, the European Union, Australia, and New Zealand. The company delivers a suite of digital health solutions, including its 'Dario' metabolic programs designed to address conditions like diabetes, hypertension, and weight management. They also offer 'Dario Musculoskeletal' for preventing and treating common MSK conditions, and 'Dario' behavioral health solutions to improve access to evidence-based care. Their offerings extend to general chronic condition management solutions and DarioEngage, a proprietary care management platform. In terms of hardware, DarioHealth provides smart glucose meters, Bluetooth-connected blood pressure cuffs, digital scales, biofeedback sensor devices, and disposables such as test strip cartridges and lancets for blood glucose monitoring systems. Furthermore, they offer comprehensive diabetes management programs that integrate lifestyle changes, healthy eating guidance, advanced tracking tools, and live coaching. Founded in 2011, the company was formerly known as LabStyle Innovations Corp. before officially changing its name to DarioHealth Corp. in July 2016. Its headquarters are located in New York, New York.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:08 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 14, 2025 | -$1.20+14.29% vs estimate | $6.75M-9.67% vs estimate |
|---|
| Q4 2024 | Mar 10, 2025 | -$0.20+16.67% vs estimate | $7.60M+2.9% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | -$2.60+27.78% vs estimate | $7.42M+0.34% vs estimate |
|---|
THE ANALYST VIEW
9 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $6.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$12.10+$0.22 (+1.85%)
Absci Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.55% below the high.
$9.24+$0.14 (+1.54%)
Innovage Holding Corp.’s quoted price sits in the upper half of its reported 52-week range, 26.9% below the high.
$24.99+$0.01 (+0.04%)
Avanos Medical, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.96% below the high.
$2.90+$0.07 (+2.47%)
Pacific Biosciences of California, Inc.’s quoted price sits in the upper half of its reported 52-week range, 15.7% below the high.
$9.66-$0.18 (-1.78%)
Verastem, Inc.’s quoted price sits in the upper half of its reported 52-week range, 10.72% below the high.
$6.67+$0.04 (+0.6%)
Myriad Genetics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 20.41% below the high.
$21.68+$0.16 (+0.74%)
Fulgent Genetics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 30.15% below the high.
$7.41+$0.17 (+2.35%)
REGENXBIO Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.23% below the high.
